Cargando…
Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro
PURPOSE: Gemcitabine (GEM) is the first-line chemotherapeutic drug for pancreatic cancer treatment in clinical practice. However, many reasons can reduce the efficacy of GEM, among which the high expression of ATP-binding cassette (ABC) transporters is a significant factor. In this study, we aimed t...
Autores principales: | Kong, Lei, Du, Jiali, Gu, Jichun, Deng, Junyuan, Guo, Yujie, Tao, Baian, Jin, Chen, Fu, Deliang, Li, Ji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152182/ https://www.ncbi.nlm.nih.gov/pubmed/35656085 http://dx.doi.org/10.3389/fsurg.2022.890412 |
Ejemplares similares
-
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018) -
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway
por: Deng, Junyuan, et al.
Publicado: (2022) -
Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo
por: Li, Ji, et al.
Publicado: (2013) -
Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014) -
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
por: Yu, Xinzhe, et al.
Publicado: (2015)